Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cue Biopharma, Inc.NASDAQ: CUE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $566K fell 35.8% year over year, behind the +21.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 61.2% from the prior quarter. Over 3 fiscal years it compounded at -19.1% a year.
Context
- Depreciation & amortization amounted to 3.5% of revenue in FY2025, down 21.8 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.8% toward the trailing-twelve-month pace of +21.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 958K USD
- Year-over-year change
- -59.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 958K | -59.2% |
| FY2024 | 2024-12-31 | 2.35M | -31.6% |
| FY2023 | 2023-12-31 | 3.44M | +90.3% |
| FY2022 | 2022-12-31 | 1.81M | +201.6% |
| FY2021 | 2021-12-31 | (1.78M) | — |
Depreciation & Amortization vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 depreciation & amortization of $2.9M is the 2nd largest of the 7 companies compared; the peer median is $286K.
- Its year-over-year change of +21.7% is the 3rd highest of 7, against a peer median of +8.0%.
- Depreciation & amortization amounts to 8.9% of revenue for CUE, versus a peer median of 35.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $2.9M | +21.7% | -19.1% | 8.9% | |
| LTM Mar 2026 | $1.23M | +12.3% | +6.9% | 86.8% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| Peer median (excluding CUE) | $286K | +8.0% | +3.2% | 35.9% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 958K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.52M | 9.5M | 8.18M | 6.85M | 4.74M |
| Change in Working Capital | (4.39M) | 356K | (934K) | (4.93M) | (3.3M) |
| Accounts Receivables | (1.73M) | 3.09M | (1.64M) | 753K | (6.5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 520.4K | 83K | 770K | (678K) | 1.13M |
| Other Working Capital | (3.18M) | (2.81M) | (63K) | (5M) | 2.08M |
| Other Non-Cash Items | (26.13K) | (454K) | 90K | 74K | 2.51M |
| Operating Cash Flow | (38.84M) | (41.81M) | (39.96M) | (36.33M) | (21.69M) |
| Capital Expenditures | (913.04K) | (171K) | 0 | (66K) | (177K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 40K |
| Purchases of Investments | 0 | (29.45M) | 0 | 0 | (16.5M) |
| Sales of Investments | 10M | 5M | 25M | 0 | 16.5M |
| Other Investing Activities | 21.55K | 6K | 2K | 98K | 212K |
| Investing Cash Flow | 9.11M | (24.61M) | 25M | 32K | 75K |
| Debt Repayment | 0 | 10M | (2M) | (4M) | (4.5M) |
| Common Stock Issued | 17.38M | 39.3M | 13.39M | 14.22M | 30.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 4.36M | 473K | 18K | 0 |
| Financing Cash Flow | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.5M) | (12.76M) | (3.1M) | (26.05M) | 4.68M |
| Free Cash Flow | (39.75M) | (41.98M) | (39.96M) | (36.4M) | (21.86M) |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.